Fenofibrate NDC 51407-006

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-006Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0006Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-006-90	51407000690	90 TABLET, FILM COATED in 1 BOTTLE (51407-006-90)Marketed from Oct 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 145 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208476
Marketing start: Feb 10, 2021
Listing expires: Dec 31, 2027
Identifiers: Product ID 51407-006_579f8403-4d3b-b8ff-e063-6394a90a2f49SPL ID 579f8403-4d3b-b8ff-e063-6394a90a2f49SPL set ID 3e611f91-e351-9558-e063-6394a90ace17RxCUI 477560, 477562UNII U202363UOS
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407000690 followed by a unit qualifier and the quantity

Package 51407-0006-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 27, 2026.

Indications (excerpt from the label)

Fenofibrate tablets are peroxisome proliferator-activated receptors (PPARα) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total choles…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208476

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208476
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 48 mg/1	Tablet, Film coatedOral	Bostal LLC	35561-249
Fenofibrate	Fenofibrate 145 mg/1	Tablet, Film coatedOral	Bostal LLC	35561-250
Fenofibrate	Fenofibrate 48 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	51407-005